Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
Brief Summary: This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome. Following wash-out, all eligible subjects will undergo a 6-week open-label dose escalation with ATR-101. Subjects who continue to be eligible will then undergo a 4-week randomized withdrawal period. It is anticipated that the overall duration of the study per subject will range from approximately 14-20 weeks.